Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2008

View Archived Issues

Intradermal influenza vaccine compares well with conventional vaccine in phase III studies

Preliminary phase I results show CS-055 well tolerated in cancer patients

Upstream's potential tropical disease treatments demonstrate signs of efficacy

ACZ-885 effective in small juvenile idiopathic arthritis, CAPS studies

Phase II study data on NGR-hTNF in different cancers presented

Enrollment completed in phase II sapacitabine trial in elderly AML patients

Summit enters codevelopment agreement with Lilly for early-stage TB program

FDA and PATH-MVI to develop tests to evaluate experimental malaria vaccines

Boston Scientific completes enrollment in PERSEUS trial of the Taxus Element stent

Genmab to discontinue development of HuMax-CD4 and will out-license other programs

New agents for neuropsychiatric disorders reported in recent patents

Recent patents disclose novel therapeutic agents for rheumatoid arthritis

New anti-HIV agents imparted in recent Metastatix patent

FDA approves AstraZeneca's Seroquel XR for bipolar depression and mania

FDA continues review of Takeda's NDA for alogliptin for type 2 diabetes

iCo provides preclinical data for iCo-009

Santarus commences marketing campaign for Glumetza

Nventa provides update on its ongoing development programs

ReGen launches Colostrinin under the name Cognase in Cyprus

FDA approves Bayer HealthCare's Kogenate for prophylaxis in hemophilia A

Archimedes reports positive results from phase III study of NasalFent in cancer pain

R&D highlights from the UBS Global Life Sciences Conference in New York: Novalar Pharmaceuticals

Phase II clinical trial of Omrix's fibrin pad suspended after incident of postoperative bleeding

Results disclosed from PHOENIX 2 phase III study with ustekinumab in psoriasis

Cardiome presents a regulatory update for Kynapid in North America

Lev receives FDA approval for Cinryze in hereditary angioedema prophylaxis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...